Examining the oleoylethanolamide supplement effects on glycemic status, oxidative stress, inflammation, and anti-mullerian hormone in polycystic ovary syndrome

Table 3 The comparison glycemic status, oxidative stress, inflammatory biomarkers and anti-Mullerian hormone of the participants in placebo and OEA group before and after the intervention

Variable		Mean ± SD Placebo (n = 43)	Mean ± SD Oleoylethanolamide (n = 44)	P1
FBS (mg/dL)	Baseline	105.19 ± 23.22	106.08 ± 22.54	0.577
	End	106.09 ± 24.5	92.14 ± 20.32	0.041
	P2	0.603	0.039
Insulin (µU/ml)	Baseline	15.77 ± 3.5	15.19 ± 2.51	0.389
	End	16 ± 3.72	9.13 ± 2.22	0.0264
	P2	0.335	0.03
HOMA-IR	Baseline	4.09 ± 0.26	3.99 ± 0.13	0.159
	End	4.19 ± 0.225	2.07 ± 0.19	0.022
	P2	0.186	0.039
TAC (mg/dL)	Baseline	1 ± 0.022	1.06 ± 0.034	0.124
	End	1.1 ± 0.025	1.98 ± 0.061	0.023
	P2	0.109	0.017
MDA (ng/ml)	Baseline	1.66 ± 0.039	1.59 ± 0.055	0.21
	End	1.6 ± 0.047	0.71 ± 0.026	0.03
	P2	0.209	0.028
TNF-α (pg/ml)	Baseline	16.49 ± 4.5	16.78 ± 4.19	0.2
	End	16.22 ± 5	12.31 ± 3.36	0.041
	P2	0.208	0.036
CRP (ng/ml)	Baseline	10.62 ± 2.8	10.14 ± 2.62	0.11
	End	10.3 ± 3.68	6.9 ± 1.59	0.029
	P2	0.19	0.031
AMH (ng/ml)	Baseline	11.88 ± 2.19	12 ± 3.25	0.397
	End	11.94 ± 3	7.59 ± 2.13	0.048
	P2	0.35	0.041

Data are expressed as means ± SD
P1: Comparison of the mean of variables between the two groups of OEA and placebo (Independent samples t-test)
P2: Comparison of mean of variables in each group at baseline and end of study (Paired samples t-test)
FBS: fasting blood sugar; HOMA-IR: homeostatic model assessment for insulin resistance; TAC: total antioxidant capacity; MDA: malondialdehyde; TNF-α: tumor necrosis factor-alpha; CRP: C-reactive protein; and AMH: anti-Mullerian hormone

ISSN: 1757-2215